ReviewCell death & disease2020
Current biomarker-associated procedures of cancer modeling-a reference in the context of IDH1 mutant glioma.
Review in Cell death & disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- Polycystins Expression in Astrocytic Gliomas.Biomedicines · 2025Article
- Development and Validation of a Prognostic Molecular Phenotype and Clinical Characterization in Grade III Diffuse Gliomas Treatment with Radio-Chemotherapy.Therapeutics and clinical risk management · 2025Article
- DKK3 Expression in Glioblastoma: Correlations with Biomolecular Markers.International journal of molecular sciences · 2024Article
- The Epigenetic Evolution of Glioma Is Determined by the IDH1 Mutation Status and Treatment Regimen.Cancer research · 2024Article
- The development of a hiPSC-based platform to identify tissue-dependencies of IDH1 R132H.Cell death discovery · 2023Article
- Molecular Biomarkers and Recent Liquid Biopsy Testing Progress: A Review of the Application of Biosensors for the Diagnosis of Gliomas.Molecules (Basel, Switzerland) · 2023Review
- Inhibitory Effect of miR-339-5p on Glioma through PTP4A1/HMGB1 Pathway.Disease markers · 2022Article
- Global mapping of cancers: The Cancer Genome Atlas and beyond.Molecular oncology · 2021Review
- Single-cell profiling of D-2-hydroxyglutarate using surface-immobilized resazurin analogs.Biosensors & bioelectronics · 2021Article
- Testing the Stability of Drug Resistance on Cryopreserved, Gene-Engineered Human Induced Pluripotent Stem Cells.Pharmaceuticals (Basel, Switzerland) · 2021Article
- A Preclinical Pipeline for Translational Precision Medicine-Experiences from a Transdisciplinary Brain Tumor Stem Cell Project.Journal of personalized medicine · 2021Review
- Opposed Interplay between IDH1 Mutations and the WNT/β-Catenin Pathway: Added Information for Glioma Classification.Biomedicines · 2021Review
- Identification of CRYABCancers · 2021Article
- Carbonic Anhydrase XII is a Clinically Significant, Molecular Tumor-Subtype Specific Therapeutic Target in Glioma with the Potential to Combat Invasion of Brain Tumor Cells.OncoTargets and therapy · 2021Article
- Article
- Integrated analysis of the genomic and transcriptional profile of gliomas with isocitrate dehydrogenase-1 and tumor protein 53 mutations.International journal of immunopathology and pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Isocitrate dehydrogenases (IDH1/2) are central molecular markers for glioblastoma. Providing in vitro or in vivo models with mutated IDH1/2 can help prepare facilities to understand the biology of these mutated genes as glioma markers, as well as help, improve therapeutic strategies. In this review, we first summarize the biology principles of IDH and its mutations and outline the core primary findings in the clinical context of neuro-oncology. Given the extensive research interest and exciting developments in current stem cell biology and genome editing, the central part of the manuscript is dedicated to introducing various routes of disease modeling strategies of IDH mutation (IDH
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.